Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Trial Profile

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Mar 2019

At a glance

  • Drugs Betamethasone-dipropionate/calcipotriol (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms PSO-FAST
  • Sponsors LEO Pharma
  • Most Recent Events

    • 12 Jul 2016 According to Leo Pharma media release, based on the results from PSO-FAST study and a phase II MUSE trial (Profile 217861), the company has launched Enstilar foam spray for psoriasis in the United Kingdom.
    • 26 Apr 2016 According to Leo Pharma media release, based on the results from this PSO-FAST study and other MUSE trial (see CTP 700217861), the company received marketing authorisation for Enstilar (calcipotriol/betamethasone dipropionate) for the topical treatment of plaque psoriasis in patients 18 years of age or older, in the United Kingdom.
    • 21 Mar 2016 Results published in a Leo Pharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top